FDA Designates Orphan Status for Pharmacyclics (PCYC) CLL Treatment
Tweet
Share
E-mailGet Alerts PCYC Hot Sheet
Join SI Premium – FREE
The FDA has designated Orphan Drug Status for Pharmacyclics (Nasdaq: PCYC) chronic lymphocyctic leukemia treatment.
Here is the link to the FDA site.
Here is the link to the FDA site.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) Receives Positive CHMP Opinion for TOFIDENCE
- Rollins (ROL) Appoints Louise S. Sams to its Board
- Workday (WDAY) Announces Resignation of Ann-Marie Campbell from Board
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
